Sign in

James Fogarty

Director at DARDEN RESTAURANTSDARDEN RESTAURANTS
Board

About James P. Fogarty

Independent director of Darden Restaurants since 2014 (tenure ~11 years in FY2025), age 57. He currently serves as CEO of FULLBEAUTY Brands (private), and is recognized by Darden’s Nominating & Governance Committee for operational and turnaround expertise with significant C‑suite experience across public and private companies. In FY2025 he chairs the Finance Committee and is a member of Nominating & Governance; the Board has affirmed his independence under NYSE rules (eight of nine nominees are independent). The Board met five times in FY2025; each incumbent director, including Fogarty, attended at least 75% of Board and committee meetings, and the Board held executive sessions at each quarterly meeting .

Past Roles

OrganizationRoleTenureCommittees/Impact
FULLBEAUTY Brands, Inc.CEOSince June 2019Operational leadership of multi-channel apparel/home retailer
Orchard BrandsCEO & Director2011–2015Led through sale; post‑sale Senior Advisor to Bluestem Group Inc. in 2015
Private InvestorInvestor2010–2011Turnaround/portfolio focus
Charming Shoppes, Inc.President, CEO & Director2009–2010Specialty apparel retail leadership
Alvarez & MarsalManaging Director1994–2009Restructuring/turnaround specialist
Lehman Brothers HoldingsPresident & COO (post‑Chapter 11)2008–2009Crisis operations leadership
American Italian Pasta Co.President & CEO2005–2008Consumer staples operations
Levi Strauss & Co.CFO2003–2005Finance leadership at global brand
The Warnaco GroupSVP & CFO; Director (for a period)2001–2003Apparel finance and governance

External Roles

OrganizationRoleTenureNotes
Current public company boardsNoneNo current public directorships
Assertio Therapeutics, Inc. (formerly Depomed)Chairman of the Board2016–2020Prior public board service within past five years

Board Governance

  • Committee assignments by year:

    CommitteeFY2023FY2024FY2025
    CompensationChair Chair; committee met 5x, independent membership Member (Comp Chair is T. Wilmott)
    FinanceMember Member Chair
    Nominating & GovernanceMember Member Member
    Audit
  • Independence: Board affirmed Fogarty is independent (only CEO Cardenas is non‑independent in FY2025) .

  • Attendance and engagement: Board met five times in FY2025; each incumbent director attended ≥75% of combined Board/committee meetings; executive sessions held at each quarterly meeting .

  • Director compensation oversight: Nominating & Governance Committee uses Pearl Meyer (independent consultant) to review director compensation; all non‑employee directors deemed independent; program draws RSUs from shareholder‑approved plan .

  • Related‑party policy: N&G reviews conflicts; Board must pre‑approve “Interested Transactions” >$120k; no related‑party transactions required to be reported for FY2025; Board concluded any ordinary‑course transactions with entities affiliated with directors were immaterial .

  • Say‑on‑pay support (signal of compensation governance):

    Year of MeetingApproval (% of votes cast)
    2022~95.9%
    2023~96.5%
    2024~95.17%

Fixed Compensation

  • Current Director Compensation Program (effective since Sept 2023):

    ComponentAmount
    Annual cash retainer (all directors)$100,000
    Annual equity grant (RSUs)$185,000 fair value
    Committee chair retainersAudit $35,000; Compensation $25,000; N&G $20,000; Finance $15,000
    Committee member retainersAudit $17,500; Compensation $12,500; N&G $10,000; Finance $7,500
    Chair of the Board$100,000 cash + $100,000 RSUs
    Lead Independent Director$60,000 RSUs
  • Fogarty’s reported director compensation:

    MetricFY2023FY2025
    Fees Earned or Paid in Cash ($)$125,934 $119,931
    Stock Awards ($)$160,030 $184,921
    Option Awards ($)
    All Other Compensation ($)$4,799 (dividend equivalents) $44,265 (dividend equivalents)
    Total ($)$290,763 $349,118

Performance Compensation

  • Annual director RSU grants and vesting:

    MetricFY2023FY2024FY2025
    RSU units granted1,219 (all non‑chair directors) 1,171 (all non‑chair directors) 1,162 (all non‑chair directors)
    Grant dateSep 21, 2022 Sep 20, 2023 Sep 18, 2024
    Grant date fair value ($)$160,030 $175,018 $184,921
    Vesting termsEarlier of 1 year or next annual meeting Earlier of 1 year or next annual meeting Earlier of 1 year or next annual meeting
  • Dividend equivalents (Fogarty):

    MetricFY2024FY2025
    RSUs that vested – dividend equivalents ($)$23,922.46 $6,241
    Deferred stock units – dividend equivalents ($)$35,580 $38,024

Directors may elect to receive immediately vested RSUs in lieu of cash fees (settlement may be deferred); RSUs earn dividend equivalents to the extent they vest .

Other Directorships & Interlocks

ItemDetail
Current public boardsNone
Prior public boards (past 5 years)Assertio Therapeutics, Inc., Chairman (2016–2020)
Compensation Committee interlocksNone; no insider participation or reciprocal interlocks reported in FY2023

Expertise & Qualifications

  • N&G Committee concluded Fogarty is qualified due to operational and turnaround experience and significant executive officer/director experience across public and private companies .
  • Extensive C‑suite finance and operations background (CFO at Levi Strauss; CEO roles at American Italian Pasta, Charming Shoppes; Managing Director at Alvarez & Marsal; crisis COO at Lehman Brothers Holdings) .

Equity Ownership

MetricValue
Beneficial ownership (common shares), as of May 25, 202532,176 shares; less than 1% of shares outstanding
RSUs counted in beneficial ownership (vested/will vest within 60 days)6,790 units
Outstanding RSUs (awards outstanding), as of May 25, 20257,952 units
Outstanding RSUs trendFY2023: 9,189 ; FY2024: 7,961 ; FY2025: 7,952
Stock ownership guidelines≥5x annual cash retainer; mandatory hold until compliance; all directors in compliance or on track as of May 25, 2025
Hedging/PledgingProhibited for directors; short sales and derivatives prohibited; pledging or margin accounts prohibited

Governance Assessment

  • Committee leadership and expertise: Fogarty’s transition from Compensation Chair (FY2023–FY2024) to Finance Chair (FY2025) aligns with his finance/turnaround background; Compensation Committee remained fully independent with defined processes and no interlocks, supporting pay governance quality .
  • Independence and attendance: Affirmed independent; attended ≥75% of meetings; Board held regular executive sessions — positive engagement signals .
  • Director pay structure and alignment: Pay mix emphasizes equity via annual RSUs with simple time‑based vesting; Fogarty’s FY2025 pay comprised $119,931 cash fees and $184,921 stock awards, plus $44,265 dividend equivalents — consistent with the standardized program and use of RSUs to align with shareholders .
  • Ownership and risk controls: Beneficial ownership of 32,176 shares, RSU accumulation, compliance/on‑track with ownership guidelines, and strict bans on hedging/pledging reduce misalignment risk; no related‑party transactions required to be reported in FY2025 .
  • Shareholder confidence indicators: Strong say‑on‑pay approvals (95–96% range across recent years) support investor confidence in compensation oversight during Fogarty’s tenure on Compensation and Finance committees .

RED FLAGS: None disclosed — no related‑party transactions, no hedging/pledging, attendance threshold met, and committee independence affirmed .